
CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.
KMT2D (lysine methyltransferase 2D) encodes a histone methyltransferase that catalyzes methylation of lysine 4 on histone H3. It functions as part of the ASCOM transcriptional regulatory complex and contributes to regulation of genes including beta-globin and estrogen receptor targets. Mutations in KMT2D cause Kabuki syndrome, making it relevant to studies of histone modification, transcriptional regulation, and developmental biology.
MS751 is a human epithelial tumor cell line established in 1974. The available information does not provide additional details regarding its tissue origin, disease background, or biological characteristics.
Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Knockout Region: E4
Reference Transcript: KMT2D-201
Validation Method: PCR amplification+Sanger sequencing
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?